WHAT IS CLAIMED IS:

1. Use of fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of ~~A method of treatment, comprising:~~

~~administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having~~ a COVID-19 infection.

2. The ~~method~~ use of claim 1, wherein the patient has or is expected to develop acute respiratory distress syndrome.

3. The ~~method~~ use of any of claims 1-2, wherein the patient has a cough but does not have acute respiratory distress syndrome.

4. The ~~method~~ use of any of claims 1-3, wherein the patient is over the age of 60 and/or has one or more other lung diseases.

5. The ~~method~~ use of claim 4, wherein the patient has or has a history of having asthma, pneumothorax, atelectasis, bronchitis, chronic obstructive pulmonary disease, lung cancer or pneumonia.

6. The ~~method~~ use of any of claims 1-5, wherein the patient has or is expected to develop acute kidney injury.

~~7. The method of any of claims 1-6, wherein the patient has reduced kidney function but does not have acute kidney injury.~~

~~8. The method of any of claims 1-7, wherein the patient is over the age of 60 and/or has one or more other kidney diseases.~~

~~9. The method of any of claims 1-8, wherein the patient has or has a history of having dialysis treatments and/or has had a kidney transplant.~~

~~10~~7. The ~~method~~ use of any of claims 1-~~6~~9, wherein the patient has or is expected to develop thrombosis.

~~11~~8. The ~~method~~ use of any of claims 1-~~9~~7, wherein the patient has a prothrombotic coagulation profile but does not have thrombosis.

~~12~~9. The ~~method~~ use of claim ~~11~~8, wherein the patient has increased levels of D-dimer.

~~13~~10. The ~~method~~ use of any of claims 1-~~12~~9, wherein the patient is over the age of 60 and/or has one or more risk factors for developing thrombosis.

~~14~~11. The ~~method~~ use of any of claims 1-~~13~~10, wherein the patient has or has had a thrombotic event.

~~15~~12. The ~~method~~ use of any of claims 1-~~14~~11, wherein the medicament is to be administered ~~administering is~~ systemically ~~administering~~.


~~16~~13. The ~~method~~ use of claim ~~15~~12, wherein the ~~administering~~ medicament is to be administered ~~done~~ orally or intravenously.

~~17. The method of any of claims 1-15, wherein the administering is done by pulmonary administration.~~

~~18. The method of claim 17, wherein the administering is done using an inhaler or nebulizer.~~


~~19. The method of any of claims 1-18, wherein the patient is in intensive care.~~

~~20~~14. The ~~method~~ use of any of claims 1-~~19~~13, wherein the active component is of the formula:




.

15. The use of any of claims 1-14, wherein fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof is is of the formula:




.

~~21~~16. Use of fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of ~~A method for treating acute respiratory distress syndrome, comprising:~~

~~administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop~~ acute respiratory distress syndrome.

~~22~~17. The ~~method~~ use of claim ~~21~~16, wherein the patient has a COVID-19 infection.

~~23. The method of any of claims 21-22, wherein the patient has or is expected to develop acute respiratory distress syndrome.~~

~~24. The method of any of claims 21-23, wherein the patient has a cough but does not have acute respiratory distress syndrome.~~

~~25. The method of any of claims 21-24, wherein the patient is over the age of 60 and/or has one or more other lung diseases.~~

~~26. The method of claim 25, wherein the patient has or has a history of having asthma, pneumothorax, atelectasis, bronchitis, chronic obstructive pulmonary disease, lung cancer or pneumonia.~~

~~27. The method of any of claims 21-26, wherein the administering is systemically administering.~~


~~28. The method of claim 27, wherein the administering is done orally or intravenously.~~

~~29. The method of any of claims 21-26, wherein the administering is done by pulmonary administration.~~

~~30. The method of claim 29, wherein the administering is done using an inhaler or nebulizer.~~

~~31. The method of any of claims 21-30, wherein the patient is in intensive care.~~

~~32~~18. The method of any of claims ~~21~~16-~~31~~17, wherein the active component is of the formula:




.

19. Use of fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of thrombosis or acute kidney injury.

~~33. A method for inhibiting a cytokine response in a patient, comprising administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response.~~

~~34. The method of claim 33, wherein the patient has a COVID-19 infection.~~

~~35. The method of claim 33 or 34, wherein the symptoms are associated with a cytokine storm.~~

~~36. The method of claim 35, wherein the symptoms are associated with acute respiratory distress syndrome and/or acute kidney injury.~~

~~37. The method of any of claims 33-36, wherein the patient is over the age of 60 and/or has one or more other lung diseases and/or kidney diseases.~~

~~38. The method of claim 37, wherein the patient has or has a history of having asthma, pneumothorax, atelectasis, bronchitis, chronic obstructive pulmonary disease, lung cancer or pneumonia.~~

~~39. The method of claim 37, wherein the patient has or has a history of having dialysis treatments and/or has had a kidney transplant.~~

~~40. The method of any of claims 33-39, wherein the administering is systemically administering.~~


~~41. The method of claim 40, wherein the administering is done orally or intravenously.~~

~~42. The method of any of claims 33-38, wherein the administering is done by pulmonary administration.~~

~~43. The method of claim 42, wherein the administering is done using an inhaler or nebulizer.~~

~~44. The method of any of claims 33-43, wherein the patient is in intensive care.~~

~~45. The method of any of claims 33-44, wherein the active component is of the formula:~~




~~.~~

~~46. A method for treating acute kidney injury, comprising:~~

~~administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute kidney injury.~~

~~47. The method of claim 46, wherein the method further comprises testing the patient for kidney malfunction.~~

~~48. The method of any of claims 46-47, wherein the patient has a COVID-19 infection.~~

~~49. The method of any of claims 46-48, wherein the patient has or is expected to develop acute kidney injury.~~

50. The method of any of claims 46-49, wherein the patient has reduced kidney function but does not have acute kidney injury.

51. The method of any of claims 46-50, wherein the patient is over the age of 60 and/or has one or more other kidney diseases.


52. The method of any of claims 46-51, wherein the patient has or has a history of having dialysis treatments and/or has had a kidney transplant.

53. The method of any of claims 46-52, wherein the administering is systemically administering.

54. The method of claim 53, wherein the administering is done orally or intravenously.

55. The method of any of claims 46-54, wherein the patient is in intensive care.

56. The method of any of claims 46-55, wherein the active component is of the formula:




57. A method for treating thrombosis, comprising:

administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop thrombosis, wherein the patient has a COVID-19 infection.

58. The method of claim 57, wherein the method further comprises testing the patient for thrombosis.

59. The method of claim 58, wherein the patient has or is expected to develop thrombosis.

60. The method of any of claims 56-59, wherein the patient has a prothrombotic coagulation profile but does not have thrombosis.

61. The method of claim 60, wherein the patient has increased levels of D-dimer.

62. The method of any of claims 56-61, wherein the patient is over the age of 60 and/or has one or more risk factors for developing thrombosis.


63. The method of any of claims 56-62, wherein the patient has or has had a thrombotic event.

64. The method of any of claims 56-63, wherein the administering is systemically administering.

65. The method of claim 64, wherein the administering is done orally or intravenously.

66. The method of any of claims 56-65, wherein the patient is in intensive care.

67. The method of any of claims 56-66, wherein the active component is of the formula:




.

68. The method of any prior claim, wherein the fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof is administered as a component of a combination therapy along with one or more of camostat mesylate, nafamostat mesylate, chloroquine phosphate, hydroxychloroquine, cepharanthine/selamectin/mefloquine hydrochloride, remdesivir, N4, hydroxyctidine, lopinavir/ritonavir, umifenovir, favipiravir, oseltamivir, N3, casirivimab, imdevimab, bamlanivimab, etesevimab, dexamethasone, prednisone, methylprednisone, hydrocortisone, baricitinib or invermetin.